Publication | Closed Access

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

MedicineSecond-line DovitinibGynecologyMetastatic Endometrial CancerCancer TreatmentCancer GeneticsOncologyRadiation OncologyMolecular Oncology